If your ponytail feels half as thick as it used to and your scalp shows through under bright light, you are not imagining it, and you are not alone. Two options that come up often in women's hair conversations work in completely different ways, and in perimenopause the reasons behind your shedding change the conversation entirely.
Why perimenopause changes the story
Female hair thinning is rarely the same picture as male pattern balding. In women, thinning tends to be diffuse: the part widens, the ponytail shrinks, and the scalp shows through, rather than a receding hairline or a bald crown. The medical term is female pattern hair loss (FPHL), and it is influenced by both genetics and hormones [1].
Perimenopause matters here because it is a period of hormonal turbulence, not a clean switch. Estrogen and progesterone fluctuate and generally decline, while the relative influence of androgens (male-type hormones that women also make) can shift [2]. Hair follicles on the top of the scalp are sensitive to androgens, and that sensitivity is part of why thinning can accelerate in the 40s and 50s [1]. This is also why being told you are "too young for menopause" can feel so dismissive: the symptoms, including hair changes, often begin years before a final period.
A provider evaluating hair loss will usually want to rule out or identify contributors first. Iron deficiency, thyroid disease, and rapid weight change are common reversible or treatable factors, so bloodwork often comes before any conversation about specific options [1][3]. There is no single "hair pill" answer; the two options below reach the same visible concern through very different biology.
Option one: oral minoxidil (a vascular and follicle-cycle mechanism)
Minoxidil was originally a blood-pressure medication. Researchers noticed increased hair growth as a side effect, and it later became widely used topically for hair. The oral form, used at low doses for hair, has drawn growing interest in dermatology, though it is prescribed off-label for this purpose [4].
The leading explanation for how it works involves the hair growth cycle. Minoxidil appears to shorten the resting (telogen) phase and prolong the active growth (anagen) phase, and it may improve blood flow to follicles [4]. Importantly, it does not act on hormones, so it is mechanism-agnostic to the androgen shifts of perimenopause. That can make it a candidate a provider considers regardless of the hormonal backdrop.
Because it started as a cardiovascular drug, the monitoring conversation centers on the cardiovascular system. Providers weigh possible effects such as changes in heart rate, fluid retention, and lightheadedness, and they consider a person's blood pressure and heart history [4]. Unwanted hair growth on the face or body is another documented consideration [4]. A well-known temporary phenomenon, an early increase in shedding as follicles synchronize into a new cycle, is something providers often explain up front so it is not mistaken for the option failing.
Option two: spironolactone (a hormonal, anti-androgen mechanism)
Spironolactone approaches the same visible thinning from an entirely different angle. It is a diuretic that also blocks androgen receptors and reduces the effect of androgens on tissues, which is why it is used off-label in women for androgen-related skin and hair concerns [1][5].
Because perimenopausal thinning can be driven in part by androgen sensitivity, an anti-androgen approach is conceptually aligned with that biology in a way the vascular mechanism is not. A provider may find this relevant when the overall clinical picture, including other androgen-related symptoms, points that direction [1][5].
The monitoring here is metabolic rather than cardiovascular. Spironolactone affects the balance of sodium and potassium, so providers watch potassium levels and kidney function, and they consider medications and conditions that also raise potassium [5]. It is not appropriate during pregnancy or attempts to conceive because of potential effects on a developing fetus, and it can affect the menstrual cycle, an important detail when cycles are already unpredictable [5]. These are exactly the kinds of nuances that a clinician who takes perimenopause seriously will want to discuss rather than gloss over.
How a provider actually weighs the two
The choice is not "which is stronger." It is which mechanism fits your biology, your health history, and what you can safely be monitored for.
A few of the questions that shape the conversation:
- What is the hormonal and lab picture? Iron studies, thyroid function, and a review of the menstrual pattern often come first [1][3].
- What is the cardiovascular vs. metabolic profile? Blood pressure and heart history point toward one monitoring path; kidney function and potassium point toward another [4][5].
- Is pregnancy possible? This single question meaningfully changes whether an anti-androgen option is even on the table [5].
- What matters most to you? Some people prioritize avoiding hormonal effects; others want an approach aligned with the androgen story.
These two options are not mutually exclusive in every clinical scenario, and neither is guaranteed to be prescribed. Whether any medication is appropriate is a decision only an independent licensed provider can make after reviewing your history and labs.
Source: [4] Low-Dose Oral Minoxidil for the Treatment of Hair Loss: Systematic Review (PubMed, NIH), [5] Spironolactone (StatPearls, NIH National Library of Medicine)
What realistic expectations look like
Hair biology is slow. The growth cycle runs over months, so any hair conversation is measured in seasons, not weeks. Providers generally frame a multi-month window before reassessing, and they emphasize that consistency and monitoring matter more than early impressions. This article does not promise any specific result; it describes how the options are commonly evaluated.
If compounded versions of any medication come up during a visit, here is the required context: Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
This article is educational and is not medical advice, diagnosis, or a recommendation to take any specific medication.
Source: [1] Female Pattern Hair Loss (StatPearls, NIH National Library of Medicine)
Where Velri fits
Velri is a technology and coordination company, not a medical provider. For hair concerns in perimenopause, Velri can help coordinate the pieces that make a real evaluation possible: relevant lab work, a visit with an independent, physician-led Provider Group, and, if a provider decides a medication is appropriate, fulfillment through an independent, licensed pharmacy.
The Velri clinical review process is built so the hormonal context of perimenopause is part of the conversation, not an afterthought, and so the monitoring each option requires is set up from the start. Care is delivered by independent Provider Groups, and a prescription is never guaranteed; it is decided by an independent licensed provider based on your history and labs. Coverage starts in Nevada, with more states rolling out over time.
